There was no difference in the primary endpoint of progression-free survival among the groups, and there was an apparent trend towards inferior overall survival in the experimental arm (14.4 vs. 19.8 months; HR 1.42; 95% CI 0.76–2.68).
1
—
—
There was no difference in the primary endpoint of progression-free survival among the groups, and there was an apparent trend towards inferior overall survival in the experimental arm (14.4 vs. 19.8 months; HR 1.42; 95% CI 0.76–2.68).